CHSJ

Curr Health Sci J, vol. 44, no. 2, 2018

Immunoexpression of Transforming Growth Factor Beta 3 (TGF?3) and Its Receptor Type III (TGF?RIII) in Basal Cell Carcinomas

[Original paper]

D. FLORESCU(1), A.E. STEPAN(2), C. MARGARITESCU(2), C.E. SIMIONESCU(2), D. STEPAN(3)


(1)PhD Student, Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania,
(2)Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania,
(3)Department of Infant Care-Pediatrics-Neonatology, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

Basal cell carcinomas (BCCs) are malignant tumors with particular biological prognosis and behavior, and the biomolecular investigation of these lesions can provide important therapeutic targets for epithelial neoplasia. In this study we analyzed the immunoexpression of transforming growth factor beta 3 (TGF?3) and its receptor type III (TGF?RIII) for 53 cases of BCC in relation to the main histopathological prognostic parameters. The results indicated statistically significant differences of TGF?3 and TGF?RIII expression related to histological type and lesion stage, the both proteins being higher expressed in adenoid and morpheaform advanced stage tumors. In this study, TGF?3 and TGF?RIII immunoexpression analysis indicated their utility for identifying aggressive BCCs with potential for tumor progression.


Keywords: transforming growth factor, basal cell carcinoma



Corresponding: Alex Emilian Stepan, Department of Pathology, University of Medicine and Pharmacy of Craiova, 66 1 May Avenue, 200628 Craiova, Romania, e-mail: astepan76@yahoo.com


DOI 10.12865/CHSJ.44.02.12 - Download PDF
current issue cover Download cover
Download contents

Journal archive